Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Aug;10(Suppl 21):S2537-S2544.
doi: 10.21037/jtd.2018.07.19.

The current state of oligometastatic and oligoprogressive non-small cell lung cancer

Vasu Tumati  1 , Puneeth Iyengar  1
Affiliations
Review

The current state of oligometastatic and oligoprogressive non-small cell lung cancer

Vasu Tumati et al. J Thorac Dis. 2018 Aug.

Abstract

Oligometastatic disease is defined as an intermediate state between localized and widespread metastatic disease. Given that in the oligometastatic state gross tumors represent the full extent of disease, there may be a role for curative local therapy despite metastatic disease. As nearly 60% of patients with non-small cell lung cancer (NSCLC) present with metastatic disease and another 45% of patients with initially localized disease will ultimately develop distant metastases, NSCLC represents a prime disease for aggressive intervention. In this review, the definition, prognostic factors, patient selection, rationale and evidence for treatment of oligoprogressive and oligometastatic NSCLC is discussed, including recent prospective trials and future directions.

Keywords: Non-small cell lung cancer (NSCLC); metastasectomy; oligometastases; oligoprogressive; stereotactic ablative radiotherapy (SABR); stereotactic body radiation therapy (SBRT).

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

References

    1. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin 2017;67:7-30. 10.3322/caac.21387 - DOI - PubMed
    1. Chen VW, Ruiz BA, Hsieh MC, et al. Analysis of stage and clinical/prognostic factors for lung cancer from SEER registries: AJCC staging and collaborative stage data collection system. Cancer 2014;120 Suppl 23:3781-92. 10.1002/cncr.29045 - DOI - PMC - PubMed
    1. Rusch VW, Rice TW, Crowley J, et al. The seventh edition of the American Joint Committee on Cancer/International Union Against Cancer Staging Manuals: the new era of data-driven revisions. J Thorac Cardiovasc Surg 2010;139:819-21. - PubMed
    1. Bradley JD, Paulus R, Komaki R, et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol 2015;16:187-99. 10.1016/S1470-2045(14)71207-0 - DOI - PMC - PubMed
    1. Weichselbaum RR, Hellman S. Oligometastases revisited. Nat Rev Clin Oncol 2011;8:378-82. 10.1038/nrclinonc.2011.44 - DOI - PubMed